Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xenazine

- PMLiVE

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

Setback for AML candidate quizartinib

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

- PMLiVE

Bad news for BMS as Keytruda kidney cancer combo approved

Opdivo and Yervoy combination will be squeezed

- PMLiVE

UniQure gets speedy US review for Huntington’s gene therapy

Pioneer gaining momentum again

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

- PMLiVE

Gottlieb signs off with flair – and pledge of further drug price commentary

Highlights issues of insulin prices and competition

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

- PMLiVE

Gottlieb admonishes industry for clinical trial failings

Calls for faster uptake of novel trial design and methods

- PMLiVE

NCI head Sharpless named as interim FDA chief

The search for a permanent replacement is still ongoing

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links